Celgene bets $6M on wound care biotech; Lilly partners up for Lou Gehrig's development;

@FierceBiotech: Gilead charts PhIII success for leukemia drug as J&J showdown awaits. More | Follow @FierceBiotech

@JohnCFierce: Check out my webinar Thursday morning with Toni Ribas and Carol Gallagher on targeted cancer drugs. More | Follow @JohnCFierce

@DamianFierce: AstraZeneca just can't wait to get to Cambridge, plans to deploy 400 scientists to get R&D ball rolling. Story | Follow @DamianFierce

@EmilyMFierce: As resistance rises, one MIT team is investigating how a bacteria-derived toxin could help design new antibiotics. Article | Follow @EmilyMFierce

> Celgene ($CELG) invested $6 million in wound care company Alliqua, also handing over marketing rights to two of its related products. More

> Eli Lilly ($LLY) teamed up with Project A.L.S. to develop treatments for amyotrophic lateral sclerosis, or Lou Gehrig's disease. Item

> Cardiome snatched up Swiss drugmaker Correvio in exchange for $12 million and 19.9% of its outstanding shares. News

> The FDA is approving more and more drugs each year, and the rate is unlikely to slow, according to a report. Story

Medical Device News

@FierceMedDev: Study: Medtronic next-gen pacer tech achieves atrial fibrillation delay. More | Follow @FierceMedDev

@MarkHFierce: Cardiovascular Systems wants to sell 2.1M shares in a public offering. Simply put: expansion requires funding. Story | Follow @MarkHFierce

@MichaelGFierce: Spoke to MIT's Dr. Robert Langer about drug delivery and nanotech. Story in tomorrow's FierceDrugDelivery report. | Follow @MichaelGFierce

> Congress faces pushback over proposed Medicare medical imaging cuts. Item

> Medtronic's otherwise stellar Q2 stained by spinal revenue declines. More

> NEJM: Stents don't beat drugs in treating clogged renal arteries. Article

Pharma News

@FiercePharma: Monday's most-read story: Takeda's new outsider CFO charged with $1B cost-cutting plan. More | Follow @FiercePharma

@EricPFierce: Patheon, DSM join forces in $2.6B deal, to create no name company with global reach. More | Follow @EricPFierce

@CarlyHFierce: U.S. approves drug tracking, compound pharmacy oversight law. Story from FiercePharmaManufacturing | Follow @CarlyHFierce

> One certainty: Drug spending will hit $1 trillion in 2014. Story

> EMA: No new safety flags in Roche's stash of unreported side effects. Report

> Philly jury hits J&J with $11M verdict in Topamax birth-defects case. Article

Pharma Manufacturing News

> Glaxo to use new technology in India plant. Report

> 2 Puerto Rico plants up next in Merck job-whacking plan. Story

> J&J, Merck KGaA roll out new China plant projects. Article

> DSM, Patheon join up in $2.6B deal. More

> U.S. approves drug tracking, compound pharmacy oversight law. Story

> Mylan recalls 480,000 bottles of blood pressure med. Item

Biotech Research News

> Tekmira's RNAi antivirals protect animals from lethal doses of Ebola, Marburg. More

> Oxford, MRC Technology team up on migraine drug discovery. Item

> First-ever 'mini-kidney' organs created from human stem cells. Story

> Bacteria-derived toxin could provide design for new antibiotics. Article

> Herb-based compounds improve learning, memory in Alzheimer's mice. News

> Compound that targets fat-burning mechanism discovered. Report

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.